BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, colorectal cancer, and cystic fibrosis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
Company Profile
Latest Presentation
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Pharmaceutical Preparation Manufacturing (325412)
SIC:
Pharmaceutical Preparations (2834)
Contact Information
Investor Relations
Noel Kurdi
VP Investor Relations and Strategy
T: 646-241-4400
noelk@biomx.com
Company Contact
BiomX, Inc.
7 Pinhas Sapir St.
Floor 2
Ness Ziona 7414002
Israel
info@biomx.com